Endocrinology of melanoma

Seminars in Surgical Oncology

Volumn 12, Issue 6, 1996, Pages 402-406

  Neifeld, James P ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

estrogen; glucocorticoids; melanoma; progesterone; steroid hormones; tamoxifen

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; PROGESTERONE; PROGESTERONE RECEPTOR; STEROID HORMONE; TAMOXIFEN;

CANCER GROWTH; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HORMONAL REGULATION; HUMAN; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ADULT; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS, PHASE II; CRICETINAE; ESTROGENS; FEMALE; GLUCOCORTICOIDS; HORMONES; HUMANS; MALE; MEGESTROL ACETATE; MELANOMA; MICE; MICE, NUDE; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGESTERONE; PROGNOSIS; PROTEIN BINDING; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, CELL SURFACE; SEX FACTORS; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0029804953     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199611/12)12:6<402::AID-SSU5>3.0.CO;2-E     Document Type: Review

References (37)

1. Stidham KR, Johnson JL, Seigler HF: Survival superiority of females with melanoma. Arch Surg 129:316-324, 1994.
2. Garbe C, Büttner P, Bertz J, et al: Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 75:2484-2491, 1995
3. Barth A, Wanek LA, Morton DL: Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg 181: 193-201, 1995.
4. Allen EP: Malignant melanoma: Spontaneous regression after pregnancy. Br Med J 2:1067, 1955.
5. Shiu MH, Schottenfeld D, Maclean B, Fortner JG: Adverse effect of pregnancy on melanoma. Cancer 37:181-187, 1976.
6. Slingluff CL, Reintgen DS, Vollmer RT, Seigler HF: Malignant melanoma arising during pregnancy. Ann Surg 211:552-559, 1990.
7. Wong JH, Sterns EE, Kopald KH, et al: Prognostic significance of pregnancy in Stage 1 melanoma. Arch Surg 124:1227-1231, 1989.
8. Mackie RM, Bufalino R, Morabito A, et al: Lack of effect of pregnancy on outcome of melanoma. Lancet 337:653-655, 1991.
9. Proctor JW, Auclair BG, Stokowski L: Endocrine factors and the growth and spread of B16 melanoma. J Natl Cancer Inst 57:1197-1198, 1976.
10. Walker MJ, Chaudhuri PK, Beattie CW, et al: Neuroendocrine and endocrine correlates to hamster melanoma growth in vitro. Surg Forum 29:151-152, 1978.
11. Feucht KA, Walker MJ, Das Gupta TK, Beattie CW: Effect of 17β-estradiol on the growth of estrogen receptor-positive human melanoma in vitro and in athymic mice. Cancer Res 48:7093-7101, 1988.
12. Hitselberger MH, Schleicher RL, Beattie CW: Effects of estradiol on estrogen receptor, progesterone receptor, and tyrosinase in hamster melanoma transplanted into athymic mice. Cancer Res 48: 3720-3727, 1988.
13. DiSorbo DM, Harris NA, Nathanson L: Suppression of DNA synthesis in NEL-M1 human melanoma cells by triamcinalone acetonide. Cancer Res 45:1633-1637, 1985.
14. Bhakoo HS, Paolini NS, Milholland RJ, et al: Glucocorticoid receptors and the effect of glucocorticoids on the growth of B16 melanoma. Cancer Res 41:1695-1701, 1981.
15. Fisher RI, Neifeld JP, Lippman ME: Oestrogen receptors in human malignant melanoma. Lancet 2:337-339, 1976.
16. Neifeld JP, Lippman ME, Fisher RI: Receptors for steroid hormones in human melanoma. Surg Forum 27:108-110, 1976.
17. Neifeld JP, Lippman ME: Steroid hormone receptors and melanoma. J Invest Dermatol 74:379-381, 1980.
18. Rümke P, Persijn JP, Korsten CB: Oestrogen and androgen receptors in melanoma. Br J Cancer 41:652-656, 1980.
19. Bhakoo HS, Milholland RJ, Lopez R, et al: High incidence and characterization of glucocorticoid receptors in human malignant melanoma. J Natl Cancer Inst 66:21-25, 1981.
20. Creagan ET, Ingle JN, Woods JE, et al: Estrogen receptors in patients with malignant melanoma. Cancer 46:1785-1786, 1980.
21. Kokoschka EM, Spona J, Knobler R: Sex steroid hormone receptor analysis in malignant melanoma. Br J Dermatol 107(suppl 23): 54-59, 1982.
22. Karakousis CP, Lopez R, Bhakoo HP, et al: Steroid hormone receptors and tamoxifen treatment in malignant melanoma. [Abstract]. In Magee PN. Foti M. Bergbauer PA (eds): Proceedings of the American Association for Cancer Research, 1980 May 28-31, and American Society of Clinical Oncology, 1980 May 26-27; San Diego. CA. Baltimore, MD: Waverly Press; 1980, Abstract C-105, 345.
23. Fernö M, Borg A, Erichsen C, et al: Estrogen and progesterone receptors in melanoma metastases with special reference to analytical methods and prognosis. Anticancer Res 4:179-182, 1989.
24. Walker MJ, Beattie CW, Patel MK, et al: Estrogen receptor in malignant melanoma. J Clin Oncol 5:1256-1261, 1987.
25. McCarty KS, Wortman J, Stowers S. et al: Sex steroid receptor analysis in human melanoma. Cancer 46:1463-1470, 1980.
26. Johnson RO, Bisel H, Andrews N, et al: Phase I clinical study of 6α-methylpregn-4-ene-3,11,20-trione (NSC-17256). Cancer Chemother Rep 50:671-673, 1966.
27. Bodenham DC, Hale B: Malignant melanoma. In Stoll BA (ed): "Endocrine Therapy in Malignant Disease." London: Saunders. 1972, 377-383.
28. Masiel A, Buttrick P, Bitran J: Tamoxifen in the treatment of malignant melanoma. Cancer Treat Rep 65:531-532, 1981.
29. Mirimanoff RO, Wagenknechi L, Hunziker N: Long-term complete remission of malignant melanoma with tamoxifen. Lancet 1:1368-1369, 1981.
30. Nesbit RA, Woods RL, Tattersall MHN, et al: Tamoxifen in malignant melanoma. N Engl J Med 301:1241-1242, 1979.
31. Telhaug R, Klepp O, Bormer O: Phase II study of tamoxifen in patients with metastatic malignant melanoma. Cancer Treat Rep 66:1437, 1982.
32. Creagan ET, Ingle JN, Green SJ, et al: Phase II study of tamoxifen in patients with disseminated malignant melanoma. Cancer Treat Rep 64:199-201, 1980.
33. Wagstaff J, Thatcher N, Rankin E, Crowther D: Tamoxifen in the treatment of metastatic malignant melanoma. Cancer Treat Rep 66: 1771, 1982.
34. Beretta G, Tabiadon D, Fossati P: Clinical evaluation of medroxiprogesterone acetate (MAP) in malignant melanoma. Cancer Treat Rep 63:1200, 1979.
35. Creagan ET, Schutt AJ, Ahmann DL, Green SJ: Phase II study of high-dose megestrol acetate in patients with advanced malignant melanoma. Cancer Treat Rep 66:1239-1240, 1982.
36. Creagan ET, Ingle JN, Schutt AJ, Schaid DJ: A prospective, randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. Am J Clin Oncol 12:152-155, 1989.
37. Cocconi G, Bella M, Calabresi F, et al: Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327:516-523, 1992.